Adipokines at the crossroad between obesity and cardiovascular disease

Thrombosis and Haemostasis

Volumn 113, Issue 3, 2015, Pages 553-566

  Molica, Filippo ^a,b   Morel, Sandrine ^b   Kwak, Brenda R ^a,b   Rohner Jeanrenaud, Françoise ^b   Steffens, Sabine ^a,c,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Adipokines; Cardiovascular disease; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; CD163 ANTIGEN; CHEMOKINE RECEPTOR; FATTY ACID; GAMMA INTERFERON; GELATINASE B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LEPTIN; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RESISTIN; ROSUVASTATIN; STRESS ACTIVATED PROTEIN KINASE; SUBTILISIN; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HUMAN; HYPERTENSION; INFLAMMATION; INTRAABDOMINAL FAT; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; THROMBOSIS; VASCULAR REMODELING; WEIGHT REDUCTION; ANIMAL; BLOOD VESSEL; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

ADIPOKINES; ADIPOSITY; ANIMALS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 84924145646     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-06-0513     Document Type: Review

References (192)

1. Wilson PW, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867–1872.
2. Isomaa B, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
3. Perez Rodrigo C. Current mapping of obesity. Nutricion hospitalaria 2013; 28 (Suppl 5): 21–31.
4. Park SY, et al. Body mass index and mortality in an ethnically diverse population: the Multiethnic Cohort Study. Eur J Epidemiol 2012; 27: 489–497.
5. Thomas EL, et al. Magnetic resonance imaging of total body fat. J Appl Physiol 1998; 85: 1778–1785.
6. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocrine Metabol Dis 2013; 14: 219–227.
7. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care 2011; 34 (Suppl 2): S371–379.
8. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol 2012; 57: 91–97.
9. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011; 58: 2047–2067.
10. Brouillard P, et al. Genetics of lymphatic anomalies. J Clin Invest 2014; 124: 898–904.
11. Kim F, et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007; 100: 1589–1596.
12. Chawla A, et al. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11: 738–749.
13. Owen MK, et al. Perivascular adipose tissue and coronary vascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 1643–1649.
14. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1–16.
15. Fain JN, et al. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004; 28: 616–622.
16. Bruun JM, et al. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005; 90: 2282–2289.
17. Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic disorders: functions and regulation. Curr Opin Lipidol 2011; 22: 365–372.
18. Zeyda M, et al. Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int J Obes 2010; 34: 1684–1694.
19. Harford KA, et al. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 2011; 70: 408–417.
20. Wu H, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007; 115: 1029–1038.
21. Feuerer M, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930–939.
22. Ilan Y, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 2010; 107: 9765–9770.
23. Hotamisligil GS, et al. Increased adipose tissue expression of tumor necrosis factor–alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415.
24. Telle-Hansen VH, et al. Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype. Genes Nutr 2013; 8: 425–434.
25. Poelkens F, et al. Physical fitness can partly explain the metabolically healthy obese phenotype in women. Exp Clin Endocrinol Diabetes 2014; 122: 87–91.
26. Tsigos C, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999; 48: 1332–1335.
27. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett 2008; 582: 117–131.
28. Popko K, et al. Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects. Eur J Med Res 2010; 15 (Suppl 2): 120–122.
29. Perreault M, et al. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One 2014; 9: e88539.
30. Mantzoros CS, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301: E567–584.
31. Caro JF, et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455–1462.
32. Kiguchi N, et al. Leptin enhances CC-chemokine ligand expression in cultured murine macrophage. Biochem Biophys Res Commun 2009; 384: 311–315.
33. Otero M, et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology 2006; 45: 944–950.
34. Bokarewa M, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789–5795.
35. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metabol J 2013; 37: 404–414.
36. Rajala MW, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671–1679.
37. Singhal NS, et al. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab 2008; 295: E331–338.
38. Patel L, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472–476.
39. Kaser S, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286–290.
40. Moore KJ, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7: 41–47.
41. McTernan PG, et al. Resistin. Curr Opin Lipidol 2006; 17: 170–175.
42. Kanda H, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494–1505.
43. Weisberg SP, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115–124.
44. Kirk EA, et al. Monocyte chemoattractant protein deficiency fails to restrain macrophage infiltration into adipose tissue [corrected]. Diabetes 2008; 57: 1254–1261.
45. Lim S, et al. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 2014; 233: 721–728.
46. Denzel MS, et al. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010; 120: 4342–4352.
47. Arita Y, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
48. Kloting N, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010; 299: E506–515.
49. Bik W, et al. Adipokines and genetic factors in overweight or obese but metabolically healthy Polish women. Neuro endocrinology letters 2010; 31: 497–506.
50. Waki H, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352–40363.
51. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319–2326.
52. Kadowaki T, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–1792.
53. Ohashi K, et al. Adiponectin promotes macrophage polarization toward an antiinflammatory phenotype. J Biol Chem 2010; 285: 6153–6160.
54. Yu JG, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968–2974.
55. Jensen MD, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989; 83: 1168–1173.
56. Mittendorfer B. Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking. Curr Opin Clin Nutr Metab Care 2011; 14: 535–541.
57. Karpe F, et al. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011; 60: 2441–2449.
58. Reeds DN, et al. Adipose tissue, hepatic, and skeletal muscle insulin sensitivity in extremely obese subjects with acanthosis nigricans. Metabolism 2006; 55: 1658–1663.
59. Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost 2013; 110: 669–680.
60. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab 2013; 98: E1610–1619.
61. De Taeye B, et al. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5: 149–154.
62. Rega G, et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 2005; 111: 1938–1945.
63. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85–101.
64. Meijer RI, et al. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep 2011; 11: 211–217.
65. Nishimura S, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15: 914–920.
66. Greif M, et al. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 781–786.
67. Ouwens DM, et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 2010; 14: 2223–2234.
68. Szasz T, Webb RC. Perivascular adipose tissue: more than just structural support. Clin Sci 2012; 122: 1–12.
69. Eringa EC, et al. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 2007; 14: 389–402.
70. Yudkin JS, et al. „Vasocrine“signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817–1820.
71. Rajsheker S, et al. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 2010; 10: 191–196.
72. Dorresteijn JA, et al. Mechanisms linking obesity to hypertension. Obes Rev 2012; 13: 17–26.
73. Barton M, et al. Obesity and risk of vascular disease: importance of endothelium–dependent vasoconstriction. Br J Pharmacol 2012; 165: 591–602.
74. Darvall KA, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223–233.
75. Gao X, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007; 115: 245–254.
76. Munzel T, et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40: 180–196.
77. Steinberg HO, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49: 1231–1238.
78. Vlasova M, Purhonen AK, Jarvelin MR, et al. Role of adipokines in obesity-associated hypertension. Acta Physiol 2010; 200: 107–127.
79. Waage A, et al. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 1990; 20: 2439–2443.
80. Romano M, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 315–325.
81. Schrader LI, et al. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007; 27: 2576–2581.
82. Lembo G, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293–297.
83. Korda M, et al. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008; 295: H1514–1521.
84. Aizawa-Abe M, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243–1252.
85. Mark AL, et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 1999; 17: 1949–1953.
86. Hall JE, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285: 17271–17276.
87. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension 2010; 56: 623–628.
88. Ozata M, et al. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84: 3686–3695.
89. Zhang L, et al. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 2010; 21: 1185–1191.
90. Langheim S, et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am J Physiol Heart Circ Physiol 2010; 298: H746–753.
91. Pfenniger A, et al. Lack of association between connexin40 polymorphisms and coronary artery disease. Atherosclerosis 2012; 222: 148–153.
92. Chuang TY, et al. Potential effect of resistin on the ET-1-increased reactions of blood pressure in rats and Ca2+ signaling in vascular smooth muscle cells. J Cell Physiol 2012; 227: 1610–1618.
93. Chen C, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299: H193–201.
94. Cao Y, et al. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009; 46: 413–419.
95. Greenstein AS, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009; 119: 1661–1670.
96. Hui X, et al. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012; 165: 574–590.
97. Dolinsky VW, et al. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010; 56: 412–421.
98. Ohashi K, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108–1116.
99. Tanida M, et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med 2007; 232: 390–397.
100. Tan KC, et al. Hypoadiponectinemia is associated with impaired endotheliumdependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765–769.
101. Verhagen SN, Visseren FL. Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 2011; 214: 3–10.
102. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–874.
103. Cheng KH, et al. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes 2008; 32: 268–274.
104. Skoog T, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376–383.
105. Verma S, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736–740.
106. Calabro P, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335–3340.
107. Lee TS, et al. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci 2009; 84: 97–104.
108. Jamaluddin MS, et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622–632.
109. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47–60.
110. Taleb S, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2691–2698.
111. Zeadin M, et al. Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2009; 29: 2069–2075.
112. Hasty AH, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001; 276: 37402–37408.
113. Wallace AM, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052–3056.
114. Shanker J, et al. Relationship of adiponectin and leptin to coronary artery disease, classical cardiovascular risk factors and atherothrombotic biomarkers in the IARS cohort. Thromb Haemost 2012; 108: 769–780.
115. Karakas M, et al. Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984–2002. Atherosclerosis 2010; 209: 220–225.
116. Couillard C, et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998; 21: 782–786.
117. Ouchi N, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296–1301.
118. Wang M, et al. Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus. Atherosclerosis 2013; 229: 62–70.
119. Arita Y, et al. Adipocyte-derived plasma protein adiponectin acts as a plateletderived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893–2898.
120. Kubota N, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863–25866.
121. Wolk R, et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007; 28: 292–298.
122. Ouedraogo R, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55: 1840–1846.
123. Ogasawara D, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009; 73: 343–351.
124. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399–409.
125. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003; 289: 2560–2572.
126. Niessen RW, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78: 1088–1092.
127. Bar J, et al. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. Thromb Haemost 1997; 78: 1255–1261.
128. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008; 100: 969–975.
129. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357–1364.
130. Aljada A, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002; 87: 1419–1422.
131. Carmeliet P, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180–3191.
132. Samarakoon R, et al. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. J Cell Physiol 2005; 204: 236–246.
133. Wu J, et al. Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009; 29: 1565–1570.
134. Singh P, et al. Leptin upregulates the expression of plasminogen activator inhibitor–1 in human vascular endothelial cells. Biochem Biophys Res Commun 2010; 392: 47–52.
135. Bodary PF, et al. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: e119–122.
136. Nakata M, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426–429.
137. Napoleone E, et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007; 5: 1462–1468.
138. Calabro P, et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J Vasc Res 2011; 48: 59–66.
139. Kato H, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224–230.
140. Restituto P, et al. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 298: E1072–1077.
141. Chen YJ, et al. Adiponectin inhibits tissue factor expression and enhances tissue factor pathway inhibitor expression in human endothelial cells. Thromb Haemost 2008; 100: 291–300.
142. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol 2012; 165: 643–658.
143. Wang Z, et al. NF-kappaB is required for TNF-alpha-directed smooth muscle cell migration. FEBS Lett 2001; 508: 360–364.
144. Takaoka M, et al. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009; 105: 906–911.
145. Shimabukuro M, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33: 1077–1084.
146. Lamers D, et al. Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells. J Cell Mol Med 2011; 15: 1177–1188.
147. Schafer K, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004; 24: 112–117.
148. Shan J, et al. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci USA 2008; 105: 19006–19011.
149. Bohlen F, et al. Leptin inhibits cell growth of human vascular smooth muscle cells. Vascul Pharmacol 2007; 46: 67–71.
150. Manka D, et al. Transplanted perivascular adipose tissue accelerates injury-induced neointimal hyperplasia: role of monocyte chemoattractant protein-1. Arterioscler Thromb Vasc Biol 2014; 34: 1723–1730.
151. Takaoka M, et al. Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue. Arterioscler Thromb Vasc Biol 2010; 30: 1576–1582.
152. Kubica J, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med 2005; 16: 173–180.
153. Momiyama Y, et al. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2011; 18: 108–114.
154. On YK, et al. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007; 71: 868–873.
155. Stephenson K, et al. Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice. Arterioscler Thromb Vasc Biol 2003; 23: 2027–2033.
156. Piatti P, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074–2081.
157. Matsuda M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487–37491.
158. Kitta Y, et al. Low adiponectin levels predict late in-stent restenosis after bare metal stenting in native coronary arteries. Int J Cardiol 2008; 131: 78–82.
159. Moldoveanu E, et al. Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem 2008; 41: 1429–1433.
160. Sako H, et al. Significance of changes in plasma adiponectin concentration after the implantation of stents in patients with stable angina. J Cardiol 2008; 52: 17–23.
161. Tziomalos K, et al. Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. Mediators Inflamm 2010; 2010: 364957.
162. Jung SH, et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J Nutr Biochem 2008; 19: 371–375.
163. James WP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905–917.
164. Filippatos TD, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53–65.
165. Samuelsson L, et al. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003; 5: 195–201.
166. Valsamakis G, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004; 53: 430–434.
167. Buchwald H, et al. Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc 2004; 292: 1724–1737.
168. Appachi S, Kashyap SR.‘Adiposopathy’ and cardiovascular disease: the benefits of bariatric surgery. Curr Opin Cardiol 2013; 28: 540–546.
169. Goktas Z, et al. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Frontiers Endocrinol 2013; 4: 69.
170. Periasamy M, et al. Bariatric surgery decreases monocyte-platelet aggregates in blood: a pilot study. Obesity Surg 2014; 24: 1410–1414.
171. Tschoner A, et al. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr Metab Cardiovasc Dis 2012; 22: 340–346.
172. Koh KK, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776–782.
173. Qu HY, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958–964.
174. Szotowska M, et al. Effect of Low-Dose Atorvastatin on Plasma Concentrations of Adipokines in Patients with Metabolic Syndrome. Kidney Blood Press Res 2012; 35: 226–232.
175. Sahebkar A. Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors. Nat Rev Cardiol 2014; 11: 12.
176. Miranda MX, et al. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/-mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J 2014; Epub ahead of print.
177. Blom DJ, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809–1819.
178. Pascual G, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759–763.
179. Rosen CJ. Revisiting the rosiglitazone story--lessons learned. N Engl J Med 2010; 363: 803–806.
180. Iwaki M, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655–1663.
181. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 26: 3148–3152.
182. Kang L, et al. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: Relative to inhibition of inflammatory responses. Biochimie 2010; 92: 789–796.
183. Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nature reviews Endocrinology 2014; 10: 143–156.
184. Wang A, et al. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J Biol Chem 2011; 286: 60–66.
185. Zulian A, et al. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 2011; 4: 27–33.
186. Teng KT, et al. Modulation of obesity-induced inflammation by dietary fats: mechanisms and clinical evidence. Nutrition J 2014; 13: 12.
187. Cammisotto PG, et al. Regulation of leptin secretion from white adipocytes by free fatty acids. Am J Physiol Endocrinol Metab 2003; 285: E521–526.
188. Ukropec J, et al. The hypotriglyceridemic effect of dietary n-3 FA is associated with increased beta-oxidation and reduced leptin expression. Lipids 2003; 38: 1023–1029.
189. Ramel A, et al. Effects of seafood consumption and weight loss on fasting leptin and ghrelin concentrations in overweight and obese European young adults. Eur J Nutr 2009; 48: 107–114.
190. Flachs P, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006; 49: 394–397.
191. Tishinsky JM, et al. Fish oil prevents high-saturated fat diet-induced impairments in adiponectin and insulin response in rodent soleus muscle. Am J Physiol Regul Integr Comp Physiol 2012; 302: R598–605.
192. Gammelmark A, et al. Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects. Nutr Res 2012; 32: 15–23.